CRN04894, a first-in-class, experimental oral medication for Cushing’s disease, led to a dose-dependent drop in blood and urine cortisol…
Articles by Steve Bryson, PhD
People with Cushing’s syndrome, a group of conditions that includes Cushing’s disease, have a three-times-higher risk of mortality compared…
Using a mouse model, scientists have found that the small molecule tubastatin A may be a potential treatment for…
The U.S. Food and Drug Administration (FDA) has approved Recorlev (levoketoconazole) to treat adults with endogenous Cushing’s syndrome for…
Mutations in the KDM1A gene are responsible for the development of a rare, food-dependent form of Cushing’s syndrome, according to…
CRN04894, a first-in-class, investigational oral medication to treat Cushing’s disease, demonstrated pharmacologic proof-of-concept with a dose-dependent suppression of…
A type of tumor in the brain’s pituitary gland, which causes Cushing’s disease, has been found to be more…
Metopirone (metyrapone) safely and successfully maintained lower levels of urinary cortisol over nine months in…
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Isturisa (osilodrostat)…
Biomarkers in a majority of Cushing’s syndrome patients with surgically induced disease remission showed a high…